These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 15721048)

  • 1. Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances.
    Danzon PM; Nicholson S; Pereira NS
    J Health Econ; 2005 Mar; 24(2):317-39. PubMed ID: 15721048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Entry decisions in the generic pharmaceutical industry.
    Morton FM
    Rand J Econ; 1999; 30(3):421-40. PubMed ID: 10558596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutical R&D performance by firm size: approval success rates and economic returns.
    DiMasi JA
    Am J Ther; 2014; 21(1):26-34. PubMed ID: 23344103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategic groups in the biopharmaceutical industry: implications for performance.
    Erden Z; von Krogh G; Nytorp C; Hultberg M
    Drug Discov Today; 2009 Aug; 14(15-16):726-30. PubMed ID: 19416760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microcap pharmaceutical firms: linking drug pipelines to market value.
    Beach R
    J Health Care Finance; 2012; 39(2):82-92. PubMed ID: 23971143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scale, scope, and spillovers: the determinants of research productivity in drug discovery.
    Henderson R; Cockburn I
    Rand J Econ; 1996; 27(1):32-59. PubMed ID: 10160535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analyses of direct and indirect impacts of a positive list system on pharmaceutical R&D investments.
    Han E; Kim TH; Jeung MJ; Lee EK
    Clin Ther; 2013 Jul; 35(7):941-9. PubMed ID: 23806327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Financial anatomy of neuroscience research.
    Dorsey ER; Vitticore P; De Roulet J; Thompson JP; Carrasco M; Johnston SC; Holloway RG; Moses H
    Ann Neurol; 2006 Dec; 60(6):652-9. PubMed ID: 17192926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in risks associated with new drug development: success rates for investigational drugs.
    DiMasi JA; Feldman L; Seckler A; Wilson A
    Clin Pharmacol Ther; 2010 Mar; 87(3):272-7. PubMed ID: 20130567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Collaboration with universities and innovate activity in the Spanish pharmaceutical industry (2003-2005)].
    D'Este P; Tribó JA; García-Romero A
    Med Clin (Barc); 2008 Dec; 131 Suppl 5():66-70. PubMed ID: 19631826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Financial risk of the biotech industry versus the pharmaceutical industry.
    Golec J; Vernon JA
    Appl Health Econ Health Policy; 2009; 7(3):155-65. PubMed ID: 19799470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impacts of the rise of Paragraph IV challenges on startup alliance formation and firm value in the pharmaceutical industry.
    Filson D; Oweis A
    J Health Econ; 2010 Jul; 29(4):575-84. PubMed ID: 20605244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. For success, focus your strengths.
    Levinson AD
    Nat Biotechnol; 1998 May; 16 Suppl():45-6. PubMed ID: 9591268
    [No Abstract]   [Full Text] [Related]  

  • 14. Rebuilding the R&D engine in big pharma.
    Garnier JP
    Harv Bus Rev; 2008 May; 86(5):68-70, 72-6, 128. PubMed ID: 18543809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How changes in drug-safety regulations affect the way drug and biotech companies invest in innovation.
    Reed SD; Califf RM; Schulman KA
    Health Aff (Millwood); 2006; 25(5):1309-17. PubMed ID: 16966727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What affects the innovation performance of small and medium-sized enterprises (SMEs) in the biotechnology industry? An empirical study on Korean biotech SMEs.
    Kang KN; Lee YS
    Biotechnol Lett; 2008 Oct; 30(10):1699-704. PubMed ID: 18506395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Causal Relationships among Technology Acquisition, Absorptive Capacity, and Innovation Performance: Evidence from the Pharmaceutical Industry.
    Jeon J; Hong S; Ohm J; Yang T
    PLoS One; 2015; 10(7):e0131642. PubMed ID: 26181440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case study of lean drug discovery: from project driven research to innovation studios and process factories.
    Ullman F; Boutellier R
    Drug Discov Today; 2008 Jun; 13(11-12):543-50. PubMed ID: 18549982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Training for GMPs.
    Levchuk JW
    J Parenter Sci Technol; 1991; 45(6):270-5. PubMed ID: 1802982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.